ABL Bio Inc.

KOSDAQ 298380.KQ

ABL Bio Inc. EBIT Margin for the year ending December 31, 2023: -0.76%

ABL Bio Inc. EBIT Margin is -0.76% for the year ending December 31, 2023, a -111.23% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

ABL Bio Inc. EBIT Margin for the year ending December 31, 2022 was 6.74%, a 100.83% change year over year.
ABL Bio Inc. EBIT Margin for the year ending December 31, 2021 was -816.12%, a -19.10% change year over year.
ABL Bio Inc. EBIT Margin for the year ending December 31, 2020 was -685.24%, a 25.95% change year over year.
ABL Bio Inc. EBIT Margin for the year ending December 31, 2019 was -925.40%, a 90.01% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

KOSDAQ: 298380.KQ

ABL Bio Inc.

CEO	Dr. Sang Hoon Lee Ph.D.
IPO Date	Dec. 19, 2018
Location	South Korea
Headquarters	16 Daewangpangyo-Ro 712 Beon-Gil
Employees	102
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. The company is headquartered in Seongnam, South Korea.

Key trends

Past 5 years